PAI Partners has agreed to divest its majority stake in Amplitude Surgical to Zydus Lifesciences for €6.25 per share, marking a significant step in the strategic expansion of Zydus into the MedTech sector.

Target Information

Amplitude Surgical, a prominent player in the field of lower-limb orthopedic technology, has experienced remarkable growth during its tenure under the ownership of PAI Partners. The company specializes in the design and manufacturing of innovative orthopedic implants and instruments that cater specifically to lower extremity surgeries. With significant advancements in its manufacturing capabilities and the introduction of a state-of-the-art surgical robot, Amplitude has solidified its position as a European leader in the orthopedic market.

In the fiscal year 2024, Amplitude Surgical reported revenues of €106 million and an EBITDA of €27.1 million, showcasing its robust operational performance. The firm has successfully expanded its international footprint and enhanced its product offerings, making it an attractive acquisition for potential investors.

Industry Overview

The orthopedic device market in Europe is an evolving sector characterized by increasing demand for innovative surgical solutions and enhanced recovery methods. As populations age and the prevalence of orthopedic conditions rises, the demand fo